DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Saturday. The brokerage issued a hold rating on the stock.

DBVT has been the topic of several other reports. JMP Securities raised their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a research report on Wednesday, July 31st. HC Wainwright reissued a buy rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st.

DBV Technologies Stock Down 2.3 %

DBVT traded down $0.02 on Friday, reaching $0.91. The company’s stock had a trading volume of 22,592 shares, compared to its average volume of 53,543. The stock has a 50 day moving average of $0.88 and a two-hundred day moving average of $1.29. The company has a market capitalization of $87.81 million, a price-to-earnings ratio of -1.08 and a beta of 0.68. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $3.70.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. During the same period in the previous year, the business posted ($0.26) earnings per share. As a group, analysts anticipate that DBV Technologies will post -1.22 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.